arrow
A

Anil A. Joy

University of Alberta
H指数:40
被引数:7,011

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025

加拿大乳腺癌实践指南:2025年早期和转移性三阴性乳腺癌患者系统性治疗的国家共识建议

2026-04-270
OAAI
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025

加拿大乳腺癌实践指南:HR+/HER2−转移性乳腺癌患者系统性治疗的国家共识建议 2025

2026-02-150
OA
Efficacy of intravascular ultrasound-guided primary percutaneous coronary intervention in acute coronary syndrome: a meta-analysis of randomized controlled trials with meta-regression

血管内超声引导下急性冠状动脉综合征患者行直接经皮冠状动脉介入治疗的疗效:一项随机对照试验的Meta分析及Meta回归研究

2026-01-010
PRE
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
2025-11-010
OA
Baseline Characteristics of Individuals with Metastatic Cancer Enrolled in the Alberta Cancer Exercise Study and 12-Week Findings for Symptom-Related and Physical Fitness Measures

入组阿尔伯塔癌症运动研究的转移性癌症患者基线特征及12周症状相关和身体机能指标的观察结果

2025-10-070
OAAI
Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials

胆固醇酯转移蛋白(CETP)抑制剂在成人高脂血症患者血脂谱中的比较效果:一项全面的系统综述和基于频率法的网络Meta分析,纳入随机对照试验。

2025-09-140
OAAI
Role of Qualified Exercise Professionals in Medical Clearance for Exercise: Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study

合格运动专业人员在外科运动许可中的作用:阿尔伯塔癌症运动混合效果-实施研究

2025-09-010
OA
The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial

DHA(二十二碳六烯酸)对DHA-WIN试验中接受新辅助化疗的乳腺癌女性患者血浆细胞因子、氧化脂质和肿瘤浸润淋巴细胞的影响

2025-07-100
PRE
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial

二十二碳六烯酸补充剂在辅助性乳腺癌治疗期间的安全性与有效性:DHA-WIN II期双盲随机对照试验的结果

2025-06-090
OA
Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial

二十二碳六烯酸(DHA)补充剂可减轻接受新辅助治疗的乳腺癌患者外周血免疫细胞在浓度、表型及反应性方面的变化。DHA-WIN试验的次要发现

2025-05-220
OA
Exploratory outcomes of the DHA WIN randomized controlled trial: Supplementing women with docosahexaenoic acid did not reduce the impact of neoadjuvant breast cancer chemotherapy on quality of life or exercise behaviour

DHA WIN随机对照试验的探索性结果:为女性补充docosahexaenoic acid并未减轻新辅助乳腺癌化疗对生活质量或运动行为的影响

2025-05-020
OA
Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial
2023-03-010
PRE